Laura Mauri, M.D., Dean J medication information . Kereiakes, M.D., Robert W. Yeh, M.D., Priscilla Driscoll-Shempp, M.B.A., Donald E. Cutlip, M.D., P. Gabriel Steg, M.D., Sharon-Lise T. Normand, Ph.D., Eugene Braunwald, M.D., Stephen D. Wiviott, M.D., David J. Cohen, M.D., David R. Holmes, Jr., M.D., Mitchell W. Krucoff, M.D., James Hermiller, M.D., Harold L. Dauerman, M.D., Daniel I. Simon, M.D., David E. Kandzari, M.D., Kirk N. Garratt, M.D., David P. Lee, M.D., Thomas K. Pow, M.D., Peter Ver Lee, M.D., Michael J. Rinaldi, M.D., and Joseph M. Massaro, Ph.D. For the DAPT Study Investigators: Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents..
But, in the brand new study the Gladstone group traced the lengthy investigative paths linking generations of researchers toward two recently developed drugs that may sometimes be curative. One is ipilimumab , which fights certain types of cancer, and the other is ivacaftor , which was approved in 2012 and has been hailed seeing that a ‘wonder drug’ against certain types of cystic fibrosis. Working backwards through the published medical literature, Williams’ group looked at the step-by-step advances that were necessary to result in the development of the two drugs. Based on the new analysis, more than 7,000 researchers from 5,700 different institutions, working in succession over a century, were had a need to develop the cancer drug ipilimumab. The birth of the cystic fibrosis medication was only somewhat less tough: 2,900 researchers with ties to 2,500 different organizations, laboring for 60 years.